^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    docetaxel

    i
    Other names: NSC 628503, RP 56976, XPR 6976, XRP-6976, NSC628503, NSC-628503, RP56976, RP-56976, XPR6976
    Company:
    Generic mfg.
    Drug class:
    Tubulin polymerization promoter, Microtubule stabilizer
    Related drugs:
    1d
    A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer (clinicaltrials.gov)
    P3, N=246, Active, not recruiting, R-Pharm
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    2d
    ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers (clinicaltrials.gov)
    P1/2, N=31, Active, not recruiting, Washington University School of Medicine | N=114 --> 31 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation
    |
    gemcitabine • docetaxel • Hepacid (pegargiminase)
    2d
    Phase II Study of LM-24C5 (clinicaltrials.gov)
    P2, N=130, Recruiting, LaNova Medicines Limited
    New P2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Avastin (bevacizumab) • docetaxel • LM-24C5
    2d
    Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov)
    P1/2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> May 2026 | Trial primary completion date: Jan 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    gemcitabine • docetaxel • hydroxychloroquine
    3d
    TroFuse-015: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (clinicaltrials.gov)
    P3, N=450, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel • docetaxel • irinotecan • Lonsurf (trifluridine/tipiracil) • Jiataile (sacituzumab tirumotecan)
    4d
    A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer (clinicaltrials.gov)
    P1, N=328, Recruiting, HC Biopharma Inc.
    New P1 trial
    |
    EGFR mutation
    |
    cisplatin • carboplatin • paclitaxel • docetaxel • pemetrexed • etoposide IV
    4d
    Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) (clinicaltrials.gov)
    P3, N=190, Active, not recruiting, Genmab | N=702 --> 190 | Trial completion date: Oct 2029 --> Sep 2028 | Trial primary completion date: Jun 2028 --> Jul 2027
    Enrollment change • Trial completion date • Trial primary completion date • Head-to-Head
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • docetaxel • acasunlimab (GEN1046)
    4d
    Impact of Immunohistochemical PSA and Ki-67 Expression on Prognosis in Metastatic Castration-Sensitive Prostate Cancer. (PubMed, Int J Urol)
    Immunohistochemical PSA and Ki-67 expression provide practical prognostic information for patients with metastatic castration-sensitive prostate cancer. Combined assessment with EOD ≥ 3 identifies a high-risk subgroup with unfavorable clinical outcomes.
    Clinical • Retrospective data • Journal
    |
    KLK3 (Kallikrein-related peptidase 3)
    |
    docetaxel • Nubeqa (darolutamide)
    5d
    PBX1-mediated transcription of AP1M2 promotes triple-negative breast cancer malignant progression and docetaxel resistance. (PubMed, Gene)
    PBX1-mediated AP1M2 facilitates cell proliferation, migration, invasion, and docetaxel resistance to accelerate TNBC malignant behavior, providing a novel target for TNBC treatment.
    Journal
    |
    PBX1 (PBX Homeobox 1)
    |
    docetaxel
    6d
    TD-NEOE3V3: Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=390, Not yet recruiting, Tang-Du Hospital | Initiation date: May 2025 --> Feb 2026
    Trial initiation date
    |
    cisplatin • docetaxel • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    6d
    IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=540, Not yet recruiting, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
    New P3 trial
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive
    |
    Herceptin (trastuzumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • IBI-354
    6d
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin